Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

NCT ID: NCT04233073

Last Updated: 2023-03-22

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-27
• Study Completion Date: 2022-01-25

Brief Summary

Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.

Detailed Description

This is a multicenter, prospective, open-label study to determine the efficacy and safety of andexanet in patients who require urgent surgery who have received 1 of the following FXa inhibitors: apixaban, rivaroxaban, edoxaban, or enoxaparin. The start of surgery must be within 15 hours following the last dose of FXa inhibitor. The primary efficacy outcome will be adjudicated by an independent Endpoint Adjudication Committee.

Conditions

Surgery

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

andexanet alfa

Andexanet is a recombinant version of human FXa

Intervention Type: DRUG

Other Intervention Names

Andexxa®; Ondexxya®

Eligibility Criteria

Inclusion Criteria

All of the following criteria must be met for the patient to be eligible:

• Either the patient or their medical proxy (or legal designee) has given written informed consent.
• Age ≥ 18 and < 85 years old.
• Requires urgent surgical intervention that must occur within 12 hours of consent, for which reversal of anti-fXa activity is judged necessary.
• Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], edoxaban [last dose 30 mg or greater] or enoxaparin [≥ 1 mg/kg/d]):
• ≤ 15 hours prior to start of surgery.
• > 15 hours prior to start of surgery or unknown time from the last dose, if documented anti fXa activity is > 100 ng/mL (> 0.5 IU/mL for enoxaparin, or over the equivalent IU/mL threshold on a low molecular weight heparin assay; see Laboratory Manual) within 2 hours prior to consent. Note: Patients enrolled in this manner should receive a high-andexanet dosing regimen.
• Have a negative pregnancy test documented prior to enrollment (for women of childbearing potential).
• Willingness to use highly effective methods of contraception through 30 days following study drug dose (for female and male patients who are fertile).

Exclusion Criteria

If a patient meets any of the following criteria, he or she is not eligible:

• Surgery for which the risk of clinically meaningful uncontrolled or unmanageable bleeding is low.
• Acute life-threatening bleeding (ISTH criteria) at the time of Screening:

1. The patient has acute-overt bleeding that is potentially life-threatening, e.g., with signs or symptoms of hemodynamic compromise, such as severe hypotension, poor skin perfusion, mental confusion, low urine output that cannot be otherwise explained.

2. The patient has overt bleeding associated with a fall in hemoglobin level by ≥2g/dL, OR, a hemoglobin ≤8 g/dL if no baseline hemoglobin is available.

3. The patient has acute bleeding in a critical area or organ, such as pericardial, intracranial, or intraspinal.

• Any surgical procedure that involves the intraoperative use of systemic, intravascular, unfractionated heparin.
• Primary procedure for efficacy assessment is a non-surgical interventional procedure (e.g, lumbar puncture, skin biopsy, cardiac catheterization, endoscopic retrograde cholangio-pancreatography).
• Expected survival of < 1 month due to comorbidity.
• Known "Do Not Resuscitate" order or similar advanced directive.
• The patient has a recent history (within 30 days prior to screening) of a diagnosed TE as follows: venous thromboembolism (including deep vein thrombosis, pulmonary embolism, intracardiac thrombus), myocardial infarction (including asymptomatic troponin elevations), disseminated intravascular coagulation, acute traumatic coagulopathy, cerebrovascular accident, transient ischemic attack, unstable angina pectoris hospitalization, or severe peripheral vascular disease.
• Acute decompensated heart failure or cardiogenic shock at the time of screening.
• The patient has sepsis or septic or severe hemorrhagic shock at the time of Screening.
• The patient has heparin-induced thrombocytopenia (with or without thrombosis).
• Inherited coagulopathy (e.g., anti-phospholipid antibody syndrome, protein C/S deficiency, Factor V Leiden) at time of Screening.
• Platelet count < 80,000/µL at the time of Screening.
• Last dose of apixaban < 2.5 mg, rivaroxaban < 10 mg, edoxaban < 30 mg, or enoxaparin 40 mg.
• The patient is pregnant or a lactating female.
• The patient has received any of the following drugs or blood products within 7 days of enrollment:

• Vitamin K antagonists (e.g., warfarin).
• Dabigatran.
• Prothrombin complex concentrate products (e.g., Kcentra®) or recombinant factor VIIa (e.g., NovoSeven®).
• Whole blood, plasma fractions. Note: Administration of tranexamic acid, platelets or packed red blood cells is not an exclusion criterion.
• The patient was treated with an investigational drug < 30 days prior to Screening.
• Prior treatment with andexanet.
• Known hypersensitivity to any component of andexanet.
• Known allergic reaction to hamster proteins.
• Known or suspected (i.e., presumed positive) COVID-19-related illness at the time of Screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alexion Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinical Trial Site

Innsbruck, , Austria

Clinical Trial Site

Klagenfurt, , Austria

Clinical Trial Site

Vienna, , Austria

Clinical Trial Site

Clermont-Ferrand, , France

Clinical Trial Site

Dijon, , France

Clinical Trial Site

Lille, , France

Clinical Trial Site

Nantes, , France

Clinical Trial Site

Paris, , France

Clinical Trial Site

Paris, , France

Clinical Trial Site

Aachen, , Germany

Clinical Trial Site

Bonn, , Germany

Clinical Trial Site

Cologne, , Germany

Clinical Trial Site

Dortmund, , Germany

Clinical Trial Site

Freiburg im Breisgau, , Germany

Clinical Trial Site

Giessen, , Germany

Clinical Trial Site

Heidelberg, , Germany

Clinical Trial Site

Konstanz, , Germany

Clinical Trial Site

Mainz, , Germany

Clinical Trial Site

Murnau am Staffelsee, , Germany

Clinical Trial Site

Würzburg, , Germany

Clinical Trial Site

Ashkelon, , Israel

Clinical Trial Site

Haifa, , Israel

Clinical Trial Site

Jerusalem, , Israel

Clinical Trial Site

Jerusalem, , Israel

Clinical Trial Site

Petah Tikva, , Israel

Clinical Trial Site

Kamakura, , Japan

Clinical Trial Site

Kasuga, , Japan

Clinical Trial Site

Kawasaki, , Japan

Clinical Trial Site

Kumamoto, , Japan

Clinical Trial Site

Kumamoto, , Japan

Clinical Trial Site

Kurume, , Japan

Clinical Trial Site

Nagoya, , Japan

Clinical Trial Site

Sakai, , Japan

Clinical Trial Site

Sendai, , Japan

Clinical Trial Site

Tokyo, , Japan

Clinical Trial Site

Phoenix, Arizona, United States

Clinical Trial Site

Tucson, Arizona, United States

Clinical Trial Site

Long Beach, California, United States

Clinical Trial Site

Moreno Valley, California, United States

Clinical Trial Site

Washington D.C., District of Columbia, United States

Clinical Trial Site

Sarasota, Florida, United States

Clinical Trial Site

Tampa, Florida, United States

Clinical Trial Site

Iowa City, Iowa, United States

Clinical Trial Site

Boston, Massachusetts, United States

Clinical Trial Site

Boston, Massachusetts, United States

Clinical Trial Site

Camden, New Jersey, United States

Clinical Trial Site

Staten Island, New York, United States

Clinical Trial Site

Charlotte, North Carolina, United States

Clinical Trial Site

Durham, North Carolina, United States

Clinical Trial Site

Columbus, Ohio, United States

Clinical Trial Site

Tulsa, Oklahoma, United States

Clinical Trial Site

Portland, Oregon, United States

Clinical Trial Site

Philadelphia, Pennsylvania, United States

Clinical Trial Site

Pittsburgh, Pennsylvania, United States

Clinical Trial Site

Pittsburgh, Pennsylvania, United States

Clinical Trial Site

Graz, , Austria

Countries

United States; Austria; France; Germany; Israel; Japan

References

Levy JH, Mamoun N. Direct oral anticoagulants and their antagonists in perioperative practice. Curr Opin Anaesthesiol. 2023 Aug 1;36(4):394-398. doi: 10.1097/ACO.0000000000001275. Epub 2023 Jun 6.

Reference Type: DERIVED

PMID: 37314165 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ALXN2070-19-515

Identifier Type: -

Identifier Source: org_study_id